Menu Search
Equities

3D Medicines Inc

1244:HKG.HZ

3D Medicines Inc

Actions
  • Price (HKD)5.64
  • Today's Change-0.14 / -2.42%
  • Shares traded525.50k
  • 1 Year change-94.75%
  • Beta--
Data delayed at least 15 minutes, as of Jun 26 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

3D Medicines Biotechnology Shanghai Co Ltd is a China-based company mainly engaged in the research and development of commercial tumor products and candidate drugs. The Company's main product pipelines including an immuno-oncology monotherapy, drug candidates with mechanisms of action amenable to combination within the pipeline, and pain management assets. The Company's core product is subcutaneous injection of anti-PD-L1, envafolimab. The Company also has a number of candidate drugs in clinical stage, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, fibroblast growth factor receptor (FGFR) 3D185 and others. The Company mainly conducts its business in the domestic market.

  • Revenue in -- (TTM)--
  • Net income in --
  • Incorporated2015
  • Employees--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.